Chalásová Katarína, Pácal Lukáš, Pleskačová Anna, Knopfová Lucia, Řehořová Jitka, Tomandlová Marie, Tomandl Josef, Kaňková Kateřina
Department of Pathophysiology, Masaryk University, Brno.
Department of Biochemistry, Masaryk University, Brno.
Exp Clin Endocrinol Diabetes. 2018 Apr;126(4):255-262. doi: 10.1055/s-0043-115009. Epub 2017 Sep 26.
Pentose phosphate pathway (PPP) with key enzyme transketolase (TKT), represents a potentially 'protective' mechanism in hyperglycaemia. Diabetic kidney disease (DKD), a common complication of both type 1 and type 2 diabetes associated with significant morbidity and mortality, represents the most common cause of chronic kidney disease (CKD). We hypothesized that protective PPP action in diabetes and eventually even more severely in concomitant DKD might be compromised by limited intracellular availability of an active TKT cofactor thiamine diphosphate (TDP).
Effect of hyperglycaemia on gene expression and protein levels of key PPP loci was studied using human cell lines relevant to diabetes (HUVEC and HRGEC) and (together with measurement of TKT activity, plasma thiamine and erythrocyte TDP concentration) in diabetic vs. non-diabetic subjects with comparable renal function (n=83 in total).
Hyperglycaemia significantly decreased protein levels of RFC-1, THTR1, THTR2 and TKT (P<0.05) . Analysis of blood samples from CKD patients with and without diabetes and from controls did not reveal any difference in gene expression and protein levels of thiamine transporters while TKT activity and TDP in erythrocytes gradually increased with decreasing kidney function being highest in patients with CKD3-4 of both diabetic and non-diabetic aetiology. Hyperglycaemia and uremic serum mimicking CKD in diabetes did not affect TKT activity (P<0.05).
Both and human experiments showed decrease or unchanged expression, respectively, of thiamine transporters induced by hyperglycaemia while TKT activity in parallel with intracellular TDP was increased in CKD patients with or without diabetes. Therefore, lack of adaptive increase of thiamine transmembrane transport allowing further increase of TKT activity might contribute to compromised PPP function in diabetes and CKD and to the development of glycotoxic injury.
戊糖磷酸途径(PPP)及其关键酶转酮醇酶(TKT)是高血糖状态下一种潜在的“保护”机制。糖尿病肾病(DKD)是1型和2型糖尿病常见的并发症,具有较高的发病率和死亡率,是慢性肾脏病(CKD)最常见的病因。我们推测,糖尿病中PPP的保护作用,以及在合并DKD时更严重的情况下,可能会因活性TKT辅因子硫胺素二磷酸(TDP)细胞内可用性受限而受到损害。
使用与糖尿病相关的人类细胞系(人脐静脉内皮细胞和人肾小球内皮细胞),并(同时测量TKT活性、血浆硫胺素和红细胞TDP浓度),研究了高血糖对糖尿病和非糖尿病且肾功能相当的受试者(共83例)中PPP关键位点基因表达和蛋白质水平的影响。
高血糖显著降低了RFC-1、THTR1、THTR2和TKT的蛋白质水平(P<0.05)。对患有和未患有糖尿病的CKD患者以及对照组的血样分析显示,硫胺素转运蛋白的基因表达和蛋白质水平没有差异,而红细胞中的TKT活性和TDP随着肾功能的下降而逐渐增加,在糖尿病和非糖尿病病因的CKD3-4期患者中最高。模拟糖尿病中CKD的高血糖和尿毒症血清不影响TKT活性(P<0.05)。
细胞实验和人体实验分别显示,高血糖诱导硫胺素转运蛋白表达降低或不变,而无论糖尿病与否,CKD患者的TKT活性与细胞内TDP平行升高。因此,硫胺素跨膜转运缺乏适应性增加,无法进一步提高TKT活性,可能导致糖尿病和CKD中PPP功能受损以及糖毒性损伤的发生。